Maximizing the Value of Data-Driven Asset Selection
In today’s competitive oncology landscape, identifying and prioritizing the right assets is critical for portfolio growth and long-term success. See how a leading biotech partnered with Evaluate to transform its in-licensing strategy, screening over 4,700 assets and leveraging a bespoke, dynamic prioritization model to select high-potential candidates for negotiation.
The Challenge
- Develop a bespoke, dynamic asset prioritization model that was aligned with the biotech’s strategy
- Deliver unbiased secondary research to evaluate the potential value of key assets of interest
- Validate the path forward for successful in-licensing and future revenue generation
Our Approach
- Longlist generation: Evaluate’s consultants generated a longlist of over 4,700 assets using data from Evaluate Pharma. They used this list to drive a discussion with key stakeholders from the client company which would be used to identify the key parameters for prioritization.
- Dynamic prioritization model: Using the range of highly-detailed data in Evaluate Pharma the consulting team then built a dynamic asset prioritization model. They used this to quantitatively compare assets at an indication-level across market factors, unmet need, and development feasibility and assess potential licensors through their likelihood to partner.
- Tailored secondary research: Armed with a list of five assets of interest, the Evaluate team conducted additional research to augment the insight gathered from Evaluate Pharma. For each of the assets, they provided detailed insight – both qualitative and quantitative.
The Impact
- 4,700 assets screened
- 1 custom asset prioritization model created
- 5 assets selected for research
